Article
Oncology
Cherie-Ann O. Nathan, D. Neil Hayes, Theodore Karrison, Olivier Harismendy, Jose M. Flores, Tara Moore-Medlin, Everett E. Vokes, J. Silvio Gutkind, Prakash Neupane, Glenn Mills, Zoukaa Sargi, Tanguy Seiwert, Juneko Grilley-Olson, Terry Day, Maura Gillison, James L. Wade, Lawrence Feldman, Gautam Jha, Mark Kozloff, Miriam O'Leary, Francis P. Worden, Ezra E. W. Cohen
Summary: This study aimed to investigate whether adjuvant everolimus, an mTOR inhibitor, improves progression-free survival in advanced-stage HNSCC patients and to explore outcomes related to disease control-associated biological factors. The results suggest that p16-negative and TP53-mutated patients may benefit from adjuvant treatment with everolimus.
CLINICAL CANCER RESEARCH
(2022)
Review
Neurosciences
Henry Querfurth, Han-Kyu Lee
Summary: mTOR is involved in regulating energy metabolism, neuronal growth, insulin signaling, and autophagy, playing both beneficial and pathogenic roles in neurodegenerative diseases. Balanced actions of mTOR complexes may have implications for Alzheimer's disease, Parkinson's disease, Huntington's disease, Frontotemporal dementia, and Amyotrophic Lateral Sclerosis. Beyond rapamycin, rapalogs with improved tolerability and delivery modes hold promise in treating age-related conditions.
MOLECULAR NEURODEGENERATION
(2021)
Review
Oncology
Katharina Joechle, Jessica Guenzle, Claus Hellerbrand, Pavel Strnad, Thorsten Cramer, Ulf Peter Neumann, Sven Arke Lang
Summary: mTORC2, a key effector of the PI3K/AKT/mTOR pathway, is associated with tumor growth, metastasis, and resistance to therapy. The central subunit Rictor of mTORC2 is upregulated in various cancers, linked to advanced tumor stages and poor prognosis, highlighting its significance in cancer development and treatment.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Mohamed El-Tanani, Hamdi Nsairat, Alaa A. Aljabali, Angel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Gowhar A. Naikoo, Walhan Alshaer, Murtaza M. Tambuwala
Summary: The mammalian target of rapamycin (mTOR), a signalling system, is necessary for various cell proliferation activities. It recognizes PI3KAKT stress signals as a serine-threonine kinase. The abnormal regulation of mTOR pathway has been proven to be crucial in cancer growth and advancement. This review primarily discusses the normal functions of mTOR as well as its abnormal roles in cancer development.
Article
Radiology, Nuclear Medicine & Medical Imaging
Jill Gluskin, Andrew Plodkowski, Jeffrey Girshman, Debra Sarasohn, Ainhoa Viteri-Jusue, Sumar Hayan, Jean Torrisi
Summary: This study found that mTOR inhibitor-associated pneumonitis often presents with a waxing and waning pattern, which may be accompanied by clinical symptoms. Recognition of this pattern may aid in promoting clinical-radiologic concordance and facilitating patient management.
Article
Biotechnology & Applied Microbiology
Wei Liu, Dong Zhao, Xiaofeng Wu, Fang Yue, Haizhen Yang, Ke Hu
Summary: Rapamycin can ameliorate obstructive sleep apnea-related renal injury by inhibiting the mTOR/NLRP3 signaling pathway, which is of great significance for the kidney health of patients with obstructive sleep apnea.
Article
Biochemistry & Molecular Biology
Alaa Abou Daher, Sahar Alkhansa, William S. Azar, Rim Rafeh, Hilda E. Ghadieh, Assaad A. Eid
Summary: Understanding the mechanisms behind diabetic nephropathy (DN) is crucial for developing effective treatments. The mTOR pathway has been identified as a key player in diabetes-induced kidney injury, through its involvement in insulin resistance, oxidative stress, and autophagy regulation.
ANTIOXIDANTS & REDOX SIGNALING
(2022)
Article
Pathology
Sambit K. Mohanty, Abhishek Satapathy, Aditi Aggarwal, Sourav K. Mishra, Nakul Y. Sampat, Shivani Sharma, Sean R. Williamson
Summary: This study found that oncocytic renal tumors with diffuse keratin 7 labeling exhibit frequent alterations in the TSC/MTOR pathway at the molecular level, despite having a morphology more similar to renal oncocytoma. This suggests an expansion of the morphologic spectrum of low-grade oncocytic tumor.
Review
Oncology
Bradley McGregor, Amir Mortazavi, Lisa Cordes, Cristina Salabao, Susan Vandlik, Andrea B. Apolo
Summary: Tyrosine kinase inhibitors combined with immune checkpoint inhibitors have been effective in treating advanced renal cell carcinoma. However, the overlapping adverse events and immune-related adverse events can complicate treatment, necessitating proper management strategies to maintain tolerability.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Robin K. Kelley, Nancy M. Joseph, Halla S. Nimeiri, Jimmy Hwang, Laura M. Kulik, Zoe Ngo, Spencer C. Behr, Courtney Onodera, Karen Zhang, Andrea G. Bocobo, Al B. Benson, Alan P. Venook, John D. Gordan
Summary: In this phase II study, the combination of temsirolimus and sorafenib demonstrated acceptable safety but did not achieve the target threshold for efficacy in hepatocellular carcinoma patients. Tumor next-generation sequencing showed mTOR pathway mutations in some patients, but these mutations were not directly associated with treatment response.
Article
Ophthalmology
Nozomi Igarashi, Megumi Honjo, Makoto Aihara
Summary: Glaucoma, the second leading cause of blindness worldwide, is often treated with trabeculectomy, but this surgery can lead to excessive scarring and tissue fibrosis. Studies have shown that mTOR inhibitors may offer a new treatment modality for reducing fibrotic response in human conjunctival fibroblasts and improving bleb scarring after filtration surgery.
EXPERIMENTAL EYE RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Mayako Uchida, Kana Nakano, Masaki Fujiwara, Yoshihiro Uesawa, Tadashi Shimizu
Summary: A comprehensive analysis of adverse events associated with everolimus therapy revealed that pulmonary and haematological AEs are frequently reported. Attention should be paid to the occurrence of lung disorders as they may lead to fatal outcomes.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Oncology
Xinglu Chen, Xiangsheng Cai, Dianpeng Zheng, Xiuya Huang, Ying Chen, Tanggang Deng, Lijun Mo, Hongwei Li, Jinlong Li, Sansan Chen
Summary: This study provides evidence that the combination of NCTD and everolimus is a potential therapeutic strategy for treating RCC and overcoming everolimus resistance by dual inhibition of mTORC1 and mTORC2 pathways.
Article
Dermatology
Mirit Gluck, Emmilia Hodak, Batya Davidovici
Summary: Immunosuppressants are crucial for graft survival in solid-organ transplant recipients, but they can lead to an increased incidence of nonmelanoma skin cancers. A retrospective study showed that mammalian target of rapamycin inhibitors (mTORi) have a sustained effectiveness in reducing the occurrence of nonmelanoma skin cancers.
DERMATOLOGIC THERAPY
(2022)
Article
Oncology
Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru P. Sonpavde
Summary: The study investigated the relationship between gene expression and treatment benefit of Everolimus in metastatic renal cell carcinoma patients. Specific gene signatures were identified that could potentially predict the response to Everolimus monotherapy or combination therapy with a vascular disrupting agent. Further validation of these gene signatures is needed to determine their clinical utility in patient selection.
MOLECULAR CANCER THERAPEUTICS
(2021)